This article is about the everyday mood fluctuations on GLP-1: the patterns you might notice week to week. For the bigger picture on mental health safety, identity shifts, and the suicide risk data, see the companion article.

Read next Your brain on GLP-1: mental health and medication

The injection cycle pattern.

Many users notice a mood pattern tied to their injection schedule:

Days 1-2 post-injection: Higher energy, better mood, stronger appetite suppression. The medication is at peak concentration.

Days 3-5: Stable middle ground. Most people feel their "normal" during this window.

Days 5-7: Mood may dip, appetite may creep back, energy may flag. The medication is at its lowest concentration before the next dose.

This pattern isn't universal, but it's common enough that recognizing it can be helpful. If you notice mood dips always happening on the same cycle day, you're likely seeing a pharmacokinetic pattern, not a personal failing.

Worth remembering
Mood tied to your injection cycle is pharmacokinetics, not a personal failing. If your dip lands on the same cycle day each week, that's the medication's concentration curve, not you.

Common mood changes.

Irritability during nausea. Hard to be cheerful when your stomach is in revolt. This usually improves as GI side effects settle.

Emotional flatness. Some people report feeling less emotional overall: fewer highs but also fewer lows. This can feel disconcerting if you're used to strong emotional reactions.

Unexpected tearfulness. Usually in the first few weeks. Can be related to hormonal shifts, caloric deficit, or the emotional weight of finally addressing something you've struggled with for years.

Improved mood. Many people experience genuinely better mood over time, driven by reduced inflammation, improved sleep, increased physical activity, and the psychological relief of food noise quieting.

What helps.

When to be concerned.

Talk to your healthcare provider if:

Crisis resources: Call or text 988 (Suicide & Crisis Lifeline) or text HOME to 741741 (Crisis Text Line).

Sources

  1. FDAFDA removes suicidal ideation warning from GLP-1 labels (Healio, 2026)
  2. META-ANALYSISGLP-1 RA and suicidal ideation: systematic review (PMC)
  3. COHORTSuicide and GLP-1 RA: case-time-control study (Lancet eClinicalMedicine)
  4. JOURNALGLP-1 RA and suicidality (American Journal of Psychiatry)
  5. COHORTDepression/anxiety/suicidal behavior in obesity + GLP-1 RA (Nature)

This article is for educational purposes only and is not medical advice. Always consult your healthcare provider about mood concerns.